<DOC>
	<DOCNO>NCT00563927</DOCNO>
	<brief_summary>To test therapeutic ratio additional chemotheray advance nasopharyngeal carcinoma .</brief_summary>
	<brief_title>Benefit Adding Chemotherapy Advance Nasopharyngeal Carcinoma ( T1-4N2-3M0 )</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Nasopharyngeal Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Squamous Cell</mesh_term>
	<mesh_term>Fluorouracil</mesh_term>
	<criteria>Undifferentiated nonkeratinizing carcinoma Tumor stag N23 No evidence distant metastasis M0 Performance status:02 Marrow : WBC &gt; = 4 platelet &gt; = 100 Renal : creatinine clearance &gt; = 60 Informed consent WHO type I squamous cell carcinoma adenocarcinoma Age &gt; = 70 Palliative intent tumor extent mandate AP oppose faciocervical field Prior malignancy except adequately treat basal cell squamous cell skin cancer , situ cervical cancer , cancer patient diseasefree 5 year Previous radiotherapy ( except nonmelanomatous skin cancer outside intend RT treatment volume Previous chemotherapy Patient pregnant lactating</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>July 2010</verification_date>
	<keyword>Nasopharyngeal Carcinoma</keyword>
	<keyword>T1-4N2-3M0</keyword>
</DOC>